EGFR and NF-κB: partners in cancer

作者: Kateryna Shostak , Alain Chariot

DOI: 10.1016/J.MOLMED.2015.04.001

关键词:

摘要: Oncogenic proteins cooperate to promote tumor development and progression by sustaining cell proliferation, survival invasiveness. Constitutive epidermal growth factor receptor (EGFR) nuclear κb (NF-κB) activities are seen in multiple solid tumors combine provide oncogenic signals cancer cells. Understanding how these pathways connected is crucial, given their role intrinsic or acquired resistance targeted anticancer therapies. We review molecular mechanisms which both EGFR- NF-κB-dependent establish positive loops increase potential. also describe NF-κB promotes EGFR inhibitors.

参考文章(83)
Kohzoh Imai, Akinori Takaoka, Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer. ,vol. 6, pp. 714- 727 ,(2006) , 10.1038/NRC1913
Weiwei Yang, Yan Xia, Yu Cao, Yanhua Zheng, Wen Bu, Lin Zhang, M. James You, Mei Yee Koh, Gilbert Cote, Kenneth Aldape, Yi Li, Inder M. Verma, Paul J. Chiao, Zhimin Lu, EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis Molecular Cell. ,vol. 48, pp. 771- 784 ,(2012) , 10.1016/J.MOLCEL.2012.09.028
Robert Roskoski, The ErbB/HER family of protein-tyrosine kinases and cancer Pharmacological Research. ,vol. 79, pp. 34- 74 ,(2014) , 10.1016/J.PHRS.2013.11.002
Linda M McAllister-Lucas, Jürgen Ruland, Katy Siu, Xiaohong Jin, Shufang Gu, David SL Kim, Peter Kuffa, Dawn Kohrt, Tak W Mak, Gabriel Nuñez, Peter C Lucas, CARMA3/Bcl10/MALT1-dependent NF-κB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells Proceedings of the National Academy of Sciences of the United States of America. ,vol. 104, pp. 139- 144 ,(2007) , 10.1073/PNAS.0601947103
C. Guo, G. R. Stark, FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-κB Proceedings of the National Academy of Sciences of the United States of America. ,vol. 108, pp. 7968- 7973 ,(2011) , 10.1073/PNAS.1105369108
Trever G. Bivona, Haley Hieronymus, Joel Parker, Kenneth Chang, Miquel Taron, Rafael Rosell, Philicia Moonsamy, Kimberly Dahlman, Vincent A. Miller, Carlota Costa, Gregory Hannon, Charles L. Sawyers, FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR Nature. ,vol. 471, pp. 523- 526 ,(2011) , 10.1038/NATURE09870
Margot Thome, Multifunctional roles for MALT1 in T-cell activation. Nature Reviews Immunology. ,vol. 8, pp. 495- 500 ,(2008) , 10.1038/NRI2338
Francisco G Pernas, Clint T Allen, Mary E Winters, Bin Yan, Jay Friedman, Bhavana Dabir, Kunal Saigal, Gerhard S Mundinger, Xiaojiang Xu, John C Morris, Katherine R Calvo, Carter Van Waes, Zhong Chen, None, Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer Clinical Cancer Research. ,vol. 15, pp. 2361- 2372 ,(2009) , 10.1158/1078-0432.CCR-08-1011
Tang Jiang, Brian Grabiner, Yifan Zhu, Changying Jiang, Hongxiu Li, Yun You, Jingyu Lang, Mien-Chie Hung, Xin Lin, CARMA3 is Crucial for EGFR-Induced Activation of NF-κB and Tumor Progression Cancer Research. ,vol. 71, pp. 2183- 2192 ,(2011) , 10.1158/0008-5472.CAN-10-3626
Josephine Kam Tai Dermawan, Katerina Gurova, John Pink, Afshin Dowlati, Sarmishtha De, Goutham Narla, Neelesh Sharma, George R. Stark, Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer Molecular Cancer Therapeutics. ,vol. 13, pp. 2203- 2214 ,(2014) , 10.1158/1535-7163.MCT-14-0013